Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Biological target

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    171 result(s) found for: Biological target. Displaying page 3 of 9.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2009-009921-28 Sponsor Protocol Number: PLOTINA Start Date*: 2010-05-15
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: The Effect of Metformin, an insulin-sensitizing drug, on Breast Cancer Primary Prevention: The Plotina Breast Cancer Prevention Randomized, Placebo Controlled Trial
    Medical condition: Breast cancer chemoprevention
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023837-45 Sponsor Protocol Number: BRF113929 Start Date*: 2011-01-26
    Sponsor Name:GlaxoSmithKline
    Full Title: BRF113929: A Phase II Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects with BRAF Mutation-Positive Metastatic Melanoma to...
    Medical condition: BRAF V600E or V600K mutation-positive metastatic melanoma to the brain
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023355-29 Sponsor Protocol Number: PO1425 Start Date*: 2011-05-18
    Sponsor Name:Papworth Hospital NHS Foundation Trust
    Full Title: Tyrosine kinase Inhibitors in DysplAsia of Lung epithelium Study 1
    Medical condition: High grade dysplasia of the bronchoepithelium
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10057004 Bronchial dysplasia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005576-28 Sponsor Protocol Number: VB-C-01 Start Date*: 2015-07-13
    Sponsor Name:VACCIBODY A.S.
    Full Title: An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women with High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3)
    Medical condition: High grade cervical intraepithelial neoplasia (HSIL, CIN 2/3)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002686-30 Sponsor Protocol Number: CEP-AZ-SH-02 Start Date*: 2009-04-15
    Sponsor Name:Christie Hospital NHS Foundation Trust
    Full Title: Assessment of the effects of the specific endothelin-A antagonist ZD4054 on prostate cancer biomarkers in patients with castrate-resistant metastatic disease
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036909 Prostate cancer metastatic LLT
    Population Age: Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006144-55 Sponsor Protocol Number: ARD6123 [AVE0005B/2001] Start Date*: 2007-03-14
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A multicenter, open-label, single-arm, two-stage study of the efficacy and safety of AVE0005 (VEGF Trap) administered intravenously every 2 weeks in patients with platinum- and erlotinib-resistant,...
    Medical condition: patients with platinum- and erlotinib-resistant, locally advanced or metastatic non-small-cell lung adenocarcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-001997-97 Sponsor Protocol Number: IFCT-0702 Start Date*: 2007-07-05
    Sponsor Name:IFCT
    Full Title: COMPARISON OF 2 CHEMOTHERAPY REGIMENS IN NON SMALL CELL LUNG CANCER PATIENTS RELAPSING AFTER SURGERY AND PERI OPERATIVE CHEMOTHERAPY A RANDOMIZED PHASE III STUDY.
    Medical condition: [1]Patients with histologically or cytologically confirmed inoperable non-small cell-lung cancer not eligible for curative radio-therapy (local or metastatic relapse). [2] Previous history of adjuv...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-002329-84 Sponsor Protocol Number: APHP211039 Start Date*: 2023-01-06
    Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (AP-HP)
    Full Title: Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial.
    Medical condition: Adult patients with aHUS associated with HE and severe kidney involvement (needing dialysis or serum creatinine ≥ 354µM).
    Disease: Version SOC Term Classification Code Term Level
    20.1 10005329 - Blood and lymphatic system disorders 10079840 Atypical haemolytic uraemic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004536-29 Sponsor Protocol Number: CHUBX2017/44 Start Date*: 2022-12-29
    Sponsor Name:CHU de Bordeaux
    Full Title: Efficacy and tolerance of the association of MTX and phototherapy versus phototherapy in adults with progressive vitiligo : a randomized double blind prospective study (METVI)
    Medical condition: Progressive vitiligo
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10047642 Vitiligo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002593-31 Sponsor Protocol Number: 69HCL19_0003 Start Date*: 2019-11-05
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Efficacy of Nintedanib per os as a treatment for epistaxis in HHT disease A national, randomized, multicenter phase II study EPICURE
    Medical condition: Hereditary Hemorrhagic Telangiectasia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10019887 Hereditary hemorrhagic telangiectasia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002632-99 Sponsor Protocol Number: ONC-NET-01 Start Date*: 2011-10-14
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: SUTNET Trial: Biological and Clinical Phase II study of Sunitinib in patients with unresectable and/or metastatic pheochromocytoma/paraganglioma
    Medical condition: Patients with unresectable and/or metastatic pheochromocytomas/paragangliomas
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001375 Adrenal neoplasm NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002393-12 Sponsor Protocol Number: PRODIGE49 Start Date*: 2016-08-26
    Sponsor Name:Fédération Francophone de Cancérologie Digestive
    Full Title: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 and targeted therapy in first-line treatment of metastatic colorectal cancer restricted to the liver
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004176-62 Sponsor Protocol Number: CLEE011AIT01 Start Date*: 2018-01-10
    Sponsor Name:NOVARTIS FARMA S.P.A.
    Full Title: A phase IIIb, open-label, local, multicenter study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2-negative advanced breast cancer on first-line treatmen...
    Medical condition: Hormone receptor-positive (HR+) HER2-negative advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001352-51 Sponsor Protocol Number: 07-116 Start Date*: 2009-01-23
    Sponsor Name:Portola Pharmaceuticals Inc.
    Full Title: A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12-Receptor Inhibitor, vs. Clopidogrel, as a Novel Antiplatelet Therapy...
    Medical condition: Adjunctive antiplatelet prior, during and after non-urgent percutaneous coronary intervention (PCI) in patients with coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065608 Percutaneous coronary intervention LLT
    9.1 10011078 Coronary artery disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019427-58 Sponsor Protocol Number: 400-10-001 Start Date*: 2010-09-08
    Sponsor Name:Omrix Biopharmaceuticals Ltd
    Full Title: A Phase III Randomized, Controlled, Superiority Study Evaluating the Fibrin Pad Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Elective Hepatic Surgery
    Medical condition: Subjects undergoing elective, open, hepatic surgery during which a resection plane is created and wherein an appropriate Target Bleeding Site is identified.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10068093 Gastrointestinal surgery LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000695-28 Sponsor Protocol Number: VitDURO-AECC17-01 Start Date*: 2018-07-04
    Sponsor Name:Hospital Universitari Germans Trias i Pujol
    Full Title: Pilot study of Vitamin D biological effects in patients with resectable urinary tract urothelial carcinoma.
    Medical condition: Patients with resectable urinary tract urothelial carcinoma candidates to radical cystectomy o nephroureterectomy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046718 Urothelial carcinoma bladder stage I, with cancer in situ LLT
    20.0 100000004864 10046720 Urothelial carcinoma bladder stage II LLT
    20.0 100000004864 10046721 Urothelial carcinoma bladder stage III LLT
    20.0 100000004864 10046724 Urothelial carcinoma ureter local LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000721-21 Sponsor Protocol Number: CA163-140 Start Date*: 2007-09-24
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Randomized Phase II study of Ixabepilone Plus Trastuzumab vs. Docetaxel Plus Trastuzumab in Female Subjects with Her2+ Locally Advanced and/or Metastatic Breast Cancer.
    Medical condition: Female Subjects with Her2+ Locally Advanced and/or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) GR (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001717-92 Sponsor Protocol Number: TarIFNiRA Start Date*: 2017-12-11
    Sponsor Name:Medical University of Vienna
    Full Title: A randomised, double-blind, placebo-controlled Phase II study to target the type I IFN receptor by administrating Anifrolumab in RA patients with a high IFN signature (TarIFNiRA)
    Medical condition: High IFN siganture in patients with rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002400-40 Sponsor Protocol Number: FFCD1709 Start Date*: 2020-07-27
    Sponsor Name:Fédération Francophone de Cancérologie Digestive
    Full Title: A PROSPECTIVE, MULTICENTER, OPEN-LABEL, PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF SELECTIVE INTERNAL RADIATION THERAPY PLUS XELOX, BEVACIZUMAB AND ATEZOLIZUMAB (IMMUNE CHEKPOINT INHIBITOR) ...
    Medical condition: MICROSATELLITE STABLE (MSS) COLORECTAL CANCER WITH LIVER-DOMINANT METASTASIS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005428-81 Sponsor Protocol Number: P140402 Start Date*: 2015-07-06
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: A Phase I/II, Open-Label, Multicentre Study to Assess The Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of AZD4547 in Patients with glioma positive for an FGFR fusion Relapsed/Refrac...
    Medical condition: Recurrent grade III or IV glioma with FGFR3-TACC3 or FGFR1-TACC1 fusion positive by RT-PCR
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 02:32:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA